Tax-loss selling is a strategy employed by some investors near year end, usually November and December. It involves selling a stock they like that is down on the year and then waiting 30 days to buy it back so a capital loss is generated to offset any capital gains for the year. If that investor fails to wait 30 days it is considered a ‘superficial loss’, which will not be recognized by the ‘tax man’. Some stocks have performed well historically during the four months between the beginning of December and the end of March, and tax-loss selling could be the reason. The top performers of this group are included in our list today.
Concordia Healthcare Corp. (TSX: CXR) - $44.34
Pharmaceuticals
Concordia Healthcare Corp. is a Canada-based diverse healthcare company that is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc., which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy.
- Market Cap: $1,932,611,705
- Percent Change (Dec 2012 - Mar 2013): 100%
- Percent Change (Dec 2013 - Mar 2014): 242%
- Percent Change (Dec 2014 - Mar 2015): 81%
Theratechnologies Inc. (TSX: TH) - $1.71
Pharmaceuticals
Theratechnologies Inc. is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing. The Company's product, EGRIFTA, is used for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy.
- Market Cap: $111,149,635
- Percent Change (Dec 2012 - Mar 2013): 10%
- Percent Change (Dec 2013 - Mar 2014): 71%
- Percent Change (Dec 2014 - Mar 2015): 165%
CRH Medical Corp. (TSX: CRH) - $3.08
Medical Equipment, Supplies & Distribution
CRH Medical Corporation is a Canada-based company that specializes in the treatment of hemorrhoids utilizing its treatment protocol and technology. The Company is focused on providing physicians with products and services for the treatment of gastrointestinal diseases. It operates in two industry segments: the sale of medical products and the provision of anesthesia services.
- Market Cap: $219,741,684
- Percent Change (Dec 2012 - Mar 2013): 54%
- Percent Change (Dec 2013 - Mar 2014): 37%
- Percent Change (Dec 2014 - Mar 2015): 232%
Related: 5 Oversold Dividend Stocks That Could Rebound Soon >>
Ballard Power Systems Inc. (TSX: BLD) - $1.96
Renewable Energy Equipment & Services
Ballard Power Systems Inc. is engaged in the development and commercialization of proton exchange membrane (PEM) fuel cells. The Company's principal business is the design, development, manufacture, sale and service of fuel cell products for a variety of applications, focusing on the telecom backup power, material handling, bus and distributed generation markets. It also offers engineering services for various fuel cell applications.
- Market Cap: $283,268,657
- Percent Change (Dec 2012 - Mar 2013): 58%
- Percent Change (Dec 2013 - Mar 2014): 254%
- Percent Change (Dec 2014 - Mar 2015): 2%
Looking for more hidden gems? Get your free Ubika Technology 20 Monthly report.
The Ubika Technology 20 index (UT20) eased 2.7% during the past month, powering past the TSX Venture Index’s 7.9% slide yet falling short of the TSX Info. Tech Index’s gain of 2.2%. Mitel Networks Corporation (TSX: MNW) was the top-performing component company this month, jumping more than 19% after reporting better-than-expected Q3 financial results. Get your copy of the Ubika Technology 20 report here >>
Resverlogix Corp. (TSX: RVX) - $1.88
Biotechnology & Medical Research
Resverlogix Corp. is a clinical-stage cardiovascular company that is developing small molecules that selectively inhibit Bromodomain and ExtraTerminal domain (BET) proteins. Its lead drug compound is RVX-208 (apabetalone). RVX-208 is a small molecule targeted for the treatment of atherosclerosis via the reduction of major adverse cardiovascular events (MACE), and also for treatment of diabetes mellitus (DM), chronic kidney disease (CKD) and Alzheimer's disease (AD).
- Market Cap: $203,292,266
- Percent Change (Dec 2012 - Mar 2013): 52%
- Percent Change (Dec 2013 - Mar 2014): 41%
- Percent Change (Dec 2014 - Mar 2015): 184%
Patient Home Monitoring Corp. (TSXV: PHM) - $0.47
Healthcare Facilities & Services
Patient Home Monitoring Corp. is engaged in providing services to patients in home monitoring and chronic disease management, as well as acquiring other companies operating in the United States healthcare service and product sectors.
- Market Cap: $141,468,079
- Percent Change (Dec 2012 - Mar 2013): 90%
- Percent Change (Dec 2013 - Mar 2014): 11%
- Percent Change (Dec 2014 - Mar 2015): 164%
